It's been a less-than-stellar year for biotech blue chip Gilead Sciences (NASDAQ: GILD). The company's stock has been mired in a pretty steady downtrend since June 2015, and, over the trailing 12 months, it's off an unsightly 26%. Mind …
Earnings drive stock price in the long run and Gilead Sciences, Inc. (NASDAQ:GILD) is entering a remarkable period of what could only be called astounding future earnings growth. This has not gone unnoticed by the market, as the stock
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …
Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren't high on the list when it came to dividends. Over the past few years, though, Amgen, Inc. (NASDAQ: AMGN) …
For the past 12 months Gilead Sciences, Inc. (NASDAQ:GILD) could have served as the poster-child for a falling knife to avoid. Many tried to catch it and lost a few fingers doing it. Calling a bottom in the stock was a fool’s errand… Until now.
Shares of Gilead and Vertex jumped Tuesday after a Bernstein analyst said Gilead should “pull the trigger” on a deal with Vertex.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Yahoo!8mon
Shares of Gilead Sciences, Inc. closed the previous trading session at 73.74 down -0.65 -0.87% with 8,910,934 shares …